- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05268289
Studie zur Wirksamkeit und Sicherheit von LNP023 bei Teilnehmern mit aktiver Lupusnephritis Klasse III-IV, +/- V
Eine adaptive, randomisierte, doppelblinde Dosiserkundung, placebokontrollierte, multizentrische Phase-2-Parallelgruppenstudie zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von LNP023 in Kombination mit Standardtherapie mit und ohne orale Kortikosteroide bei Patienten mit aktivem Lupus Nephritis Klasse III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Santa Fe, Argentinien, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasilien, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Novartis Investigative Site
-
Juiz de Fora, Minas Gerais, Brasilien, 36010-570
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 04038-002
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasilien, 01308-050
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100034
- Novartis Investigative Site
-
Shenzhen, China, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, China, 530022
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- Novartis Investigative Site
-
-
-
-
-
Mainz, Deutschland, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Deutschland, 38126
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Deutschland, 51109
- Novartis Investigative Site
-
-
-
-
-
Marseille, Frankreich, 13005
- Novartis Investigative Site
-
Nantes, Frankreich, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hongkong, 999077
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, Indien, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Indien, 226014
- Novartis Investigative Site
-
-
-
-
-
Montería, Kolumbien, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Kolumbien, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Kolumbien, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Kolumbien, 680003
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malaysia, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaysia, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malaysia, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexiko, 20230
- Novartis Investigative Site
-
Veracruz, Mexiko, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexiko, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexiko, 97070
- Novartis Investigative Site
-
-
-
-
-
Quezon, Philippinen, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Philippinen, 1218
- Novartis Investigative Site
-
-
-
-
-
Carnaxide, Portugal, 2799-523
- Novartis Investigative Site
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
Lisbon, Portugal, 1649-035
- Novartis Investigative Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Novartis Investigative Site
-
-
-
-
-
San Juan, Puerto Rico, 00927
- FDI Clinical Research
-
-
-
-
Singapore
-
Singapore, Singapore, Singapur, 308433
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08036
- Novartis Investigative Site
-
Ciudad Real, Spanien, 13005
- Novartis Investigative Site
-
Madrid, Spanien, 28034
- Novartis Investigative Site
-
Madrid, Spanien, 28040
- Novartis Investigative Site
-
Seville, Spanien, 41009
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul, Fatih, Türkei (türkiye), 34093
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Türkei (türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Türkei (türkiye), 16059
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Türkei (türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Türkei (türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungarn, 1083
- Novartis Investigative Site
-
Szeged, Ungarn, 6725
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Ungarn, 4032
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095
- Ronald Reagan UCLA Medical Center
-
San Bernardino, California, Vereinigte Staaten, 92408
- Loma Linda University
-
Sylmar, California, Vereinigte Staaten, 91342
- Olive View UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Denver
-
-
Florida
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Royal Research Corp
-
Orlando, Florida, Vereinigte Staaten, 32806
- Nephrology Associates Of Central FL
-
Riverview, Florida, Vereinigte Staaten, 33578
- Florida Kidney Physicians
-
-
Illinois
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Nep Assoc of Northern Illinois
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Wichita Community Clcl Onco Program
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Health System
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins Hospital
-
-
New York
-
East Setauket, New York, Vereinigte Staaten, 11733
- Stony Brook Internists PC
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Temple University
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75204
- Dallas Nephrology Associates
-
Houston, Texas, Vereinigte Staaten, 77054
- Prolato Clinical Research Center
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Novartis Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Andere Namen:
|
|
Placebo-Komparator: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Aktiver Komparator: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Andere Namen:
|
|
Aktiver Komparator: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Andere Namen:
|
|
Aktiver Komparator: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Zeitfenster: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Zeitfenster: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Zeitfenster: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Zeitfenster: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Zeitfenster: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Zeitfenster: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Zeitfenster: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Zeitfenster: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Bindegewebserkrankungen
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Störungen beim Wasserlassen
- Urologische Manifestationen
- Glomerulonephritis
- Nephritis
- Pathologische Zustände, Anzeichen und Symptome
- Haut- und Bindegewebserkrankungen
- Anzeichen und Symptome
- Lupus erythematodes, systemisch
- Lupusnephritis
- Proteinurie
- Verwaltung des Gesundheitswesens
- Qualität, Zugang und Bewertung im Gesundheitswesen
- Qualität der Gesundheitsversorgung
- Qualitätsindikatoren, Gesundheitsversorgung
- Sorgfalt
- Iptacopan
Andere Studien-ID-Nummern
- CLNP023K12201
- 2021-002046-33 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .